<DOC>
	<DOCNO>NCT01946854</DOCNO>
	<brief_summary>Appendiceal cancer rare disease cause many symptom . As , doctor sure chemotherapy actually effect disease . The goal clinical research study learn effect chemotherapy may appendiceal cancer .</brief_summary>
	<brief_title>Crossover Trial Systemic Chemotherapy Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group ( cohort ) : - If Cohort A , first observe 6 month , receive chemotherapy 6 month . - If Cohort B , first receive chemotherapy 6 month , observe 6 month . You equal chance assign either cohort . No matter cohort , type chemotherapy receive depend standard care disease doctor think best interest . You sign separate consent form chemotherapy explain drug give , well risk benefit . Study Visits : Every 3 month ( +/- 2 week ) 12 month : - You physical exam , include measurement weight blood pressure . - Your performance status record . - Blood ( 2 tablespoon ) draw routine test . - You complete 3 questionnaire quality life . - You MRI CT scan check status disease . Length Stud : You study 12 month . You longer able take part study disease get bad , intolerable side effect occur , unable follow study direction . Your active participation study end-of-treatment visit . End-of-Treatment Visit : The end-of-treatment visit 4th study visit . Twelve ( 12 ) month ( +/- 4 week ) begin study , follow test procedure perform : - You physical exam , include measurement weight blood pressure . - Your performance status record . - Blood ( 2 tablespoon ) draw routine test . - You complete questionnaire complete screen . - If one perform within 4 week visit , MRI CT scan check status disease . Long-Term Follow-Up : After end-of-treatment visit , follow 1 time year check medical record seeing . If nothing medical record , call ask . This call last 5-10 minute . This investigational study . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Pseudomyxoma Peritonei</mesh_term>
	<criteria>1 . Patients must histological evidence metastatic well differentiate moderately differentiate mucinous appendiceal epithelial neoplasm ( AEN ) . 2 . Radiographic image demonstrate presence mucinous peritoneal carcinomatosis ( PMP ) . 3 . Patients must consider candidate complete surgical cytoreductive surgery . This determination make either discussion MD Anderson peritoneal surface malignancy multidisciplinary review consultation MD Anderson peritoneal surgeon . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 . 5 . Age &gt; /= 18 year old . 6 . Patients must able understand provide answer European Organisation Research Treatment Cancer ( EORTC ) QLQC30/OV28 QOL questionnaires order participate trial . 7 . Adequate bone marrow function evidence : Hemoglobin &gt; /= 9.0 g/dl ; Platelet &gt; /= 75,000 cells/mm^3 ; Absolute neutrophil count &gt; /= 1000/mm^3 . 8 . Women must pregnant lactating . Women childbearing potential must negative BetaHCG serum pregnancy test agree refrain breastfeeding , specify informed consent give unknown risk teratogenicity agent study . Patients childbearing potential agree use effective form contraception chemotherapy 90 day follow last chemotherapy treatment . 9 . Patients must agree participate able understand provide inform consent participate trial . 1 . Concurrent uncontrolled medical illness deem investigator potential interfere delivery chemotherapy six month time period . 2 . Patients receive concurrent investigational therapy receive investigational therapy within 30 day first schedule day protocol treatment . 3 . The presence complete partial bowel obstruction base upon clinical assessment . 4 . Ongoing use total parental nutrition . 5 . The presence concurrent nonappendiceal metastatic cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gastrointestinal</keyword>
	<keyword>Metastatic Well-differentiated Mucinous Appendiceal Adenocarcinomas Pseudomyxoma Peritonea</keyword>
	<keyword>Appendiceal cancer</keyword>
	<keyword>Surgically unresectable</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Observation</keyword>
	<keyword>Questionnaires</keyword>
</DOC>